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Inhibitors of the activation of platelet aggrega-
tion have promise as important therapeutic
agents for the management of acute coronary
syndrome (ACS). Platelet activation by thrombin,
a serine protease, occurs by binding to and clea-
vage of the extracellular N-terminal domains of
protease-activated receptors 1 and 4 (PAR1 and
PAR4). The proteolysis of the PARs exposes new
tethered ligands that then signal through trans-
membrane domains to initiate platelet activation
as a downstream effect. A pentapeptide cleavage
product of bradykinin with the sequence Arg-
Pro-Pro-Gly-Phe serves as a thrombin inhibitor by
blocking a- and c-thrombin-induced platelet
aggregation. Analogs of RPPGF have been pre-
pared that result in improved inhibition of throm-
bin activation of platelets. Specific amino acid
residues required for activity against platelet
aggregation have been identified, and a lead
compound, rOicPaPhe(p-Me)-NH2 (FM19), has
been developed. FM19, which completely inhibits
threshold c-thrombin-induced platelet aggregation
at a concentration of 16 ± 4 lM, represents an
important lead compound in the development of
inhibitors of thrombin-mediated platelet aggrega-
tion for treatment of ACS.
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Acute coronary syndrome (ACS) refers to a number of conditions,
from unstable angina to myocardial infarction (MI), which most
often develop as a result of reduced coronary artery blood supply
because of ruptured atherosclerotic plaque (1). Approximately 90%
of MIs result from an acute thrombus that obstructs an atheroscler-
otic coronary artery (1). Therefore, modulating the activity of the
hemostatic system is both treatment and prevention of these
serious and too often fatal medical conditions.
Thrombin has an important role in hemostasis and thrombosis by
being the main clotting enzyme as well as a potent platelet activa-
tor (2). Thrombin has two substrates on platelets, protease-activa-
ted receptors 1 and 4 (PAR1 and PAR4), that when stimulated lead
to platelet activation. The PARs are G-protein-coupled receptors that
have a novel mechanism in which an extracellular proteolytic
cleavage event is translated into a transmembrane signal. These
receptors carry their own ligand, which remains cryptic until an
N-terminal fragment of the receptor is cleaved by thrombin (3).
Once activated by thrombin-mediated proteolysis, these G-protein-
coupled receptors' tethered ligands bind intramolecularly to induce
signaling to activate platelets (4). To date, only inhibitors to arachi-
donic acid- or ADP-induced platelet aggregation have been
developed for clinical use. Development of inhibitors to thrombin-
induced platelet activation would advance the field.
Bradykinin, a nonapeptide, is released from the plasma proteins,
high- and low-molecular weight kininogen through the action of
plasma kallikrein (5). Bradykinin increases vascular permeability,
dilates blood vessels, contracts non-vascular smooth muscle, and
causes pain. This short-lived vasodilator is degraded by angioten-
sin-converting enzyme to produce a pentapeptide with sequence
Arg-Pro-Pro-Gly-Phe (RPPGF) (6). This pentapeptide, along with kini-
nogen and bradykinin, inhibits thrombin-induced platelet activation
and aggregation by interacting with the active site of thrombin and
with the thrombin cleavage sites of PAR1 and PAR4 receptors (7,8).
Therefore, RPPGF and its analog rOicPGF-NH2 are leads for the
development of a selective and potent inhibitor of thrombin-induced
platelet activation (9,10). This study reports substitutions made to
the rOicPGF-NH2 sequence designed to produce a more potent
thrombin receptor activation inhibitor for the management of ACS,
and describes the discovery of a novel lead compound.
Materials and Methods
Peptides and reagents
Standard single-letter abbreviations are used to describe L-amino
acids and lowercase letters are used to represent D-amino acids.
RPPGF and rOicPGF were synthesized by Multiple Peptides Systems,
Inc. (San Diego, CA, USA). The remaining peptides were prepared
by standard solid-phase peptide synthesis methods on a Applied
Biosystems, Inc. (Foster City, CA, USA) Model 431A peptide synthes-
izer (11,12). The peptides were assembled on peptide amide linker
polyethylene glycol polystyrene (PAL-PEG-PS) resin (Applied Biosys-
tems, Warrington, UK) using standard Fmoc-based chemistry (13).
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The protected amino acids Fmoc-D-Arg (Pbf), Fmoc-Phe(p-Me), Fmoc-
Phe(p-Br), Fmoc-Phe(p-I), Fmoc-Phe(p-NO2), Fmoc-Pro, Fmoc-Oic,
Fmoc-D-Ser(t-Bu), Fmoc-Lys(biotin), and Fmoc-D-Ala were obtained
from Advanced ChemTech (Louisville, KY, USA). Unless otherwise
stated, all reagents were HPLC grade and purchased from Fisher
Scientific (Fair Lawn, NJ, USA).
The synthesis occurred in a cycle that was initiated by the swelling
of the resin (0.25 mmol) in dichloromethane (DCM) followed by de-
protection or removal of the Fmoc group from the resin with piperi-
dine (Aldrich, Milwaukee, WI, USA), followed by extensive solvent
wash and, subsequently, by coupling of Fmoc-protected amino acid
(1 mmol). Coupling was facilitated by o-benzotriazol-1-yl-N,N,N¢,N¢-
tetramethyl uronium hexafluorophosphate (HBTU; Applied Biosys-
tems), which was dissolved in a solution of 1-hydroxybenzotriazole
(HOBt; Applied Biosystems) and N,N-dimethylformamide (DMF). The
protected amino acid was dissolved in the HBTU/HOBt solution
along with additional N-methylpyrrolidone (NMP). The reaction was
carried out in the presence of 2.0 M N,N-diisopropylethylamine
(DIEA; Applied Biosystems), which created the basic environment
necessary for the activation of the amino acid residue (14). The
activated amino acid reacted with the deprotected amino-terminal
of the growing peptide chain. The final step in each coupling cycle
involved acetylation of unreacted amino groups by addition of 10-
fold excess of 0.5 M acetic anhydride, 0.125 M DIEA, and 0.015 M
HOBt in NMP. This sequence of steps was repeated until the full-
length, resin-bound peptide was completed. The resin was filtered
and washed with DCM and ethyl alcohol (EtOH) to complete the
solid-phase synthesis.
Trifluoroacetic acid/H2O/thioanisole/ethylenedithiol solution (9:0.5:
0.25:0.25, v/v/v/v; Pierce, Rockford, IL, USA)/(Applied Biosystems)
was used to cleave the peptide from the resin and simultaneously
remove the side chain-protecting groups. The peptide solution was
filtered from the resin and then subjected to preparative reverse-
phase high-performance liquid chromatography (RP-HPLC) to afford
the target peptide. The HPLC conditions were: column, Vydac C18,
2.5 · 22 cm; mobile phase, (A) water with 0.1% TFA, (B) aceto-
nitrile with 0.1% TFA; gradient, (A/B) from 100/0 to 60/40 over
80 min; flow rate, 10 mL/min; detection, UV at 230 nm. The purity
of all peptides was ‡99% as analyzed by HPLC. Final product
molecular weight was confirmed by electrospray mass spectrometry
(ThermoFinnigan, San Jose, CA, USA).
Platelet aggregation
Each peptide was examined for its ability to inhibit c-thrombin-
induced platelet aggregation of human platelet-rich plasma (PRP) as
described by Hasan et al. (8,10). Fresh whole blood from normal
human donors was collected into a syringe containing 3.8% sodium
citrate, to a final concentration of 0.38% sodium citrate (1:9 cit-
rate/blood). Whole blood was centrifuged at 180 · g (Beckman
GRP Centrifuge, Schaumburg, IL, USA) for 10 min at room tempera-
ture to prepare PRP. Platelet-poor plasma (PPP) was prepared by
centrifugation of PRP at 1000 · g for 20 min at room temperature
or by centrifugation at 10 000 · g for 2 min (Microcentrifuge E,
Beckman Instruments, Palo Alto, CA, USA). The platelets were coun-
ted on a Coulter counter (Model Z, Coulter Electronics, Hialeah, FL,
USA), and PRP was adjusted to a platelet count of 2.5 · 108 plate-
lets/mL, using PPP prior to all platelet aggregation studies. A Chro-
nolog dual-channel aggregometer (Havertown, PA, USA) was used
to assess platelet aggregation by recording the increase in light
transmittance through a stirred suspension of PRP maintained at
37 C in the cuvette. Variable concentrations of c-thrombin (Haema-
tologic Technologies, Essex Junction, VT, USA) were added to the
PRP to determine the threshold concentration for maximal percent-
age aggregation, i.e. the minimal concentration of the agonist to
induce full aggregation and secretion. c-Thrombin (Haematologic
Technologies; approximately 3000 U/mg specific activity) was used
for these studies because this form of the enzyme is unable to bind
and proteolyze plasma fibrinogen in plasma to produce a clot. Pep-
tides were dissolved in fresh HEPES-Tyrodes buffer (pH ¼ 7.40) and
added at concentrations ranging from 5 lM to 1 mM to the PRP in
the cuvette, allowing the baseline to stabilize. Platelet aggregation
was initiated by the addition of threshold amounts of c-thrombin
(usually 30–70 nM for human platelets) determined for that donor on
the day of examination. The aggregation was allowed to proceed for
5 min and the minimal concentration of each peptide to achieve
100% inhibition of platelet aggregation (IC100) was determined.
Results and Discussion
To develop analogs related to RPPGF with increased potency for
inhibition of thrombin-induced platelet aggregation, we focused our
initial efforts on substituting residues at positions 4 and 5. Previous
work employing both combinatorial methods and rational drug
design indicated that the substitution of the first residue with D-Arg
and replacement of Pro2 by Oic, known to improve potency of bra-
dykinin antagonists; while maintaining proline in the third position
of the sequence, led to pronounced improvements in potency, and
resulted in the lead compound, rOicPGF-NH2 (TH146) (10,15,16). The
goal of the current efforts was to optimize the remaining positions
by preparing analogs with substitutions at Xxx4 and Xxx5. The
results of these substitutions are summarized in Tables 1 and 2,
where data are reported as the minimal concentration of the inhib-
itor to completely block threshold c-thrombin-induced platelet
aggregation (7,8,10). Several previously synthesized and reported
compounds are also included for comparison.
Table 1 presents compounds with replacements for Gly at position
4 of rOicPGF-NH2 (TH146). As glycine has no side chain and can
assume conformations allowed for both L- and D-amino acids, alan-
ine, the most conservative substitution for glycine, was examined in
both L- and D-configurations (compounds 1 and 2, respectively). As
seen in Table 1, compound 2, which showed 100% inhibition of
platelet aggregation at 56 lM, is 10-fold more potent than com-
pound 1 and 2.5-fold more potent then TH146 in c-thrombin-
induced platelet aggregation.
The successful results observed during the testing of 2, encouraged
us to explore further D-amino acid substitutions in position 4. Among
the remaining D-amino acid-substituted analogs, compound 3, rOic-
PnF-NH2 showed a modest improvement over TH146 with 100% inhi-
bition of platelet aggregation at 83 lM, slightly less potent than 2.
The remaining analogs in this series had similar activity independent
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of the chemical nature of the residue side chain. Consequently, the
trend observed in these peptides was that the requirement for residue
4 seemed to be primarily related to the configuration of the amino
acid residue, with the actual side chain having a relatively modest
effect. A possible explanation is that the D-stereochemistry moves the
side chain 'out of the way' while helping to orient the rest of the
molecule. This assumption would be consistent with the optimal
activity displayed by 2, with the small alanine side chain.
In parallel with the examination of varying Xxx4, we also varied
Xxx5 of the lead compound TH146. The data for the rOicPG-Xxx5-
NH2 series are presented in Table 2, in which it is clearly observed
that L-amino acids are preferred over D-amino acids. This trend is
exemplified in the sharp decrease in activity in compound 18, with
D-phenylalanine at position 5 (IC100 ¼ 833 lM), in comparison with
TH146 (IC100 ¼ 140 lM). In addition, it appears that larger aromatic
groups are preferred while aliphatic and polar groups are not well
tolerated. The most potent compound in this series, compound 14,
replaces Phe5 with 2-Nal5 in rOicPGXxx5-NH2 resulting in a three-
fold improvement over TH146 (IC100 ¼ 50 lM).
Following the results from our two initial series, we attempted to
combine the best substitutions observed in the singly modified Xxx4
and Xxx5 series, but unfortunately the results do not appear to be
additive. On the contrary, as shown in Table 3, the projected best
analog, compound 25 is only slightly more potent than TH146
(IC100 ¼ 100 lM). The explanation for the observed result may be
related to steric and conformational restrictions imposed on the
doubly substituted peptide, with a less flexible backbone (due to
D-alanine at position 4) and the bulky side chain of 2-Nal. Thus, we
chose to examine other possible aromatic replacements for 2-Nal at
position 5.
Consequently, as shown in Table 3, we introduced several variations
of Phe that, like the successful 2-Nal5 substitution, were larger, aro-
matic, and lipophilic. In the initial analogs of the rOicPG-Xxx5-NH2
series, we chose to use Phe derivatives as a means of probing the
requirements for interaction with the target receptor. Phe is present
in the original lead, RPPGF, and, as seen in Table 2, the aromatic
nature of Phe5, appears to be essential for inhibition of platelet
activation. As a first group, we chose to use small (methyl), inter-
mediate (chloro), and large (biphenyl) lipophilic substituents at the
para-position of the phenyl ring of phenylalanine. In this initial
small sample of synthesized analogs, there was a clear preference
for the smallest substituent at the para-position of Phe. The
p-methylphenylalanine containing compound 27 was 3.5-fold more
potent than compound 2, 42.5-fold more potent than RPPGF, and
had a ninefold increase in potency relative to TH146 in c-thrombin-
induced platelet aggregation.
Table 4 presents the results from our attempts to examine the key
features of 27 that are required for its anticoagulant activity. In
this series, we selected a variety of Phe derivatives with a wide
range of substituents. We also examined several analogs that
retained the p-methylphenylalanine at the fifth position, but inclu-
ded modifications at the fourth position that had shown activity in
the rOicP-Xxx4-Phe(p-Me)-NH2 series. As seen in Table 4, several
Table 2: Modifications at position 5 with gly at position 4
Compounds Sequence
Inhibition of threshold
platelet aggregation (lM € SEMa)
RPPGFb RPPGF 680 € 280
TH146 rOicPGF-NH2 140 € 20
14 rOicPG-2-Nal-NH2 50 € 0
15 rOicPGE-NH2 NE
16 rOicPG-Nle-NH2 NE
17 rOicPGF(p-F)-NH2 200 € 0
18 rOicPGf-NH2 833 € 144




23 rOicPGY-NH2 300 € 100
aData presented are the mean € SEM of n > 3 independent experiments.
The values given represent the minimal concentration of peptide necessary
to inhibit 100% of threshold c-thrombin-induced platelet aggregation (IC100).
NE represents no effect or ‡1000 lM activity.
bFrom Hasan et al. (7).
Table 3: Modifications at position 5 with D-ala in position 4
Compounds Sequence
Inhibition of threshold
platelet aggregation (lM € SEMa)
RPPGFb RPPGF-NH2 680 € 280
TH146 rOicPGF-NH2 140 € 20
24 rOicPaF-NH2 56 € 16
25 rOicPa-2-Nal-NH2 100 € 35
26 rOica-Bip-NH2 200 € 100
27 (FM19) rOicPaF(p-Me)-NH2 16 € 4
aData presented are the mean € SEM of n > 3 independent experiments.
The values given represent the minimal concentration of peptide necessary
to inhibit 100% of threshold c-thrombin-induced platelet aggregation (IC100).
bFrom Hasan et al. (7).
Table 1: Modifications at position 4 with phe at position 5
Compounds Sequence
Inhibition of threshold
platelet aggregation (lM € SEMa)
RPPGFb RPPGF 680 € 280
TH146 rOicPGF-NH2 140 € 20
1 rOicPAF-NH2 550 € 166
2 rOicPaF-NH2 56 € 16
3 rOicPnF-NH2 83 € 17
4 rOicPkF-NH2 133 € 33
5 rOicPfF-NH2 133 € 33
6 rOicPpF-NH2 167 € 33
7 rOicPlF-NH2 300 € 100
9 rOicPdF-NH2 567 € 233
10 rOicPqF-NH2 400 € 100
11 rOicP-(D-Abu)-F-NH2 275 € 75
12 rOicP-(D-Orn)-F-NH2 250 € 87
13 rOicP-(D-Nle)-F-NH2 275 € 75
aData presented are the mean € SEM of n > 3 independent experiments.
The values given represent the minimal concentration of peptide necessary
to inhibit 100% of threshold c-thrombin-induced platelet aggregation (IC100).
bFrom Hasan et al. (7).
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analogs display potency comparable with that of 27. In particular
29, 33, and 36 are essentially equipotent with 27. Although
incomplete, these initial structure–activity relationship (SAR) data
suggest that lipophilic para-substituents on Phe5 lead to favorable
results and that, as observed in Table 1, small D-amino acids are
preferred in position 4 of the peptide. Further SAR studies are in
progress.
Conclusions
Several trends were observed in this series of peptides synthesized
with the aim of inhibiting thrombin-mediated platelet aggregation.
The fourth position of the peptide rOicPGF-NH2 has a preference for
D-amino acids, but is relatively indiscriminant with regard to the
actual amino acid residue and its side chain properties. The pres-
ence of an aromatic ring on the side chain of the amino acid in
position 5 is preferred over all other amino acid side chains, with
Phe(p-Me) displaying the best activity thus far. In compound 27,
[rOicPaPhe(p-Me)-NH2], known as FM19, we have developed a
more potent inhibitor (IC100 ¼ 16 lM) of c-thrombin-induced plate-
let aggregation, which represents an order of magnitude improve-
ment over previous RPPGF-related inhibitors. Further studies are
underway to extend the SARs of FM19-related analogs and eluci-
dating its mechanism of action.
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aThe data represent the fold increase in concentration of the peptide neces-
sary to inhibit threshold c-thrombin-induced platelet aggregation when com-
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